Non-contrast magnetic resonance venography with Inhance 3D Velocity: diagnostic performance for intracranial venous thrombosis

Özpar, Rıfat; Tonkaz, Mehmet; Erkal, Duygu; Ongen, Gokhan; Hakyemez, Bahattin

doi:10.1007/s00234-021-02710-1

Cited by 2 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is established that using both CE-MRV and non-contrast MRV (i.e., phase-contrast MRV and Inhance 3D Velocity useful when the use of gadolinium contrast is contraindicated), unilateral decreased signal/nonvisualization of the TS do not allow to differentiate them from TS thrombosis. [16][17][18][19][20][21][22][23][24][25][26][27][28][29] Recently, Zhu et al 30 reported that Time-Resolved MRA (TR-MRA) had higher accuracy in distinguishing TS thrombosis from TS hypoplasia.…”

Section: Discussionmentioning

confidence: 99%

“…A lot of MR sequences have been proposed for the comprehensive examination of acute CVT, none of them being able to make an accurate diagnosis by itself. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Contrastenhanced MR venography has long been the reference standard. 6,11,12 Susceptibility-weighted imaging is valuable for characterization of intracranial hemorrhage.…”

Section: Introductionmentioning

confidence: 99%

“…A lot of MR sequences have been proposed for the comprehensive examination of acute CVT, none of them being able to make an accurate diagnosis by itself. 1-16 Contrast-enhanced MR venography has long been the reference standard. 6,11,12…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of susceptibility-weighted angiography (SWAN) and T2 gradient-echo sequences for the detection of acute cerebral venous thrombosis

2022

View full text Add to dashboard Cite

Objectives To assess the diagnostic accuracy and lesion conspicuity of susceptibility-weighted angiography (SWAN) and T2* for the clot detection in acute cerebral venous thrombosis (CVT) by comparison with contrast-enhanced MR venography. Methods Venous thrombi detection and conspicuity were assessed by two readers for 18 venous segments on both T2*, SWAN source images, 2D SWAN reformats matching with T2*, and 3D SWAN images (SWAN-MinIP). Images obtained with the three reading techniques were systematically scored and compared to CE MRV findings, in a blinded fashion, per patient and per segment, and compared to each other. Results In 30 patients, 137 thrombosed venous segments were evaluated. The sensitivity of T2*, SWAN source images, 2D SWAN, and SWAN MinIP were, respectively, of 89.3%/82.1%, 82.1%, and 82.1% for dural sinus thrombosis and of 100%/100%/100%/96.6% for cortical venous thrombosis. There were significant differences in thrombus detection between T2* and SWAN: T2* versus SWAN source images and 2D SWAN ( p = 0.04) and versus SWAN MinIP ( p = 0.03). There were no significant differences between the three modalities of SWAN images. T2* was more sensitive than all SWAN images for both sigmoid sinus thrombosis and intracranial internal jugular vein thrombosis ( p = 0.04). Inter-observer agreement was slightly superior with T2* ( p < 0.05). Conclusion In this small cohort, SWAN sequence at 3T did not yield additional value for thrombus detection in acute CVT compared to T2*. This study highlights SWAN’s greatest weakness both for diagnostic accuracy and lesion conspicuity compared to T2* for acute venous clot detection near the skull base.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of susceptibility-weighted angiography (SWAN) and T2 gradient-echo sequences for the detection of acute cerebral venous thrombosis

2022

View full text Add to dashboard Cite

show abstract

“…Zudem erlaubt die cMRT die Abklärung eines breiteren differenzialdiagnostischen Spektrums und kann auch kleinere Thromben direkt darstellen. [18,19]. Die dazu verwendeten T1-Sequenzen zeigen Methämoglobin bereits nativ signalintens und liefern zudem den besten Kontrast für paramagnetische Kontrastmittel wie Gadolinium.…”

Section: Bildgebung Der Vakzininduzierten Cvstunclassified

Hirnvenen- und Sinusthrombose nach COVID-19-Schutzimpfung

et al. 2021

View full text Add to dashboard Cite

Cerebral venous sinus thrombosis after COVID-19 vaccination. Neurological and radiological managementBackground: Vaccine-induced cerebral venous and sinus thrombosis (VI-CVST) is a rare complication in recipients of the adenovirus-vectored coronavirus disease 2019 (COVID-19) vaccine ChAdOx1 nCov-19 (Vaxzevria ® ; AstraZeneca).Objectives: Development of a diagnostic and therapeutic standard. Materials and methods: Analysis of clinical and basic research findings, expert opinions, and experience with our own cases. Results: VI-CVST usually manifests on day 4-24 after vaccination, mostly in individuals aged < 60 years, and women. In the majority there is an immune pathogenesis caused by antibodies against platelet factor 4/polyanion complexes, leading to thrombotic thrombocytopenia which can result in severe, sometimes fatal, course. The cardinal symptom is headache worsening within days which, however, also can be of variable intensity. Other possible symptoms are seizures, visual disturbance, focal neurological deficits and signs of increased intracranial pressure. If VI-CVST is suspected, the determination of plasma D-dimer level, platelet count, and screening for heparininduced thrombocytopenia (HIT-2) are essential for treatment decision-making. Magnetic resonance imaging (MRI) with venous MR-angiography is the neuroimaging modality of choice to confirm or exclude VI-CVST. On T2* susceptibility-weighted MRI, the clot in the sinuses or veins produces marked susceptibility artifacts ("blooming"), which also enables the detection of isolated cortical venous thromboses. MRI/MRangiography or computed tomography (CT)/CT-angiography usually allow-in combination with clinical and laboratory findings-reliable diagnosis of VI-CVST. Conclusions: The clinical suspicion of VI-CVST calls for urgent laboratory and neuroimaging workup. In the presence of thrombocytopenia and/or pathogenic antibodies, specific medications for anticoagulation and immunomodulation are recommended.

show abstract

Non-contrast magnetic resonance venography with Inhance 3D Velocity: diagnostic performance for intracranial venous thrombosis

Cited by 2 publications

References 23 publications

Comparison of susceptibility-weighted angiography (SWAN) and T2 gradient-echo sequences for the detection of acute cerebral venous thrombosis

Comparison of susceptibility-weighted angiography (SWAN) and T2 gradient-echo sequences for the detection of acute cerebral venous thrombosis

Hirnvenen- und Sinusthrombose nach COVID-19-Schutzimpfung

Contact Info

Product

Resources

About